PET imaging of a Ga labeled modified HER2 affibody in breast cancers: from xenografts to patients.

OBJECTIVE

Overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancers provides promising opportunities for imaging and targeted therapy. Developing HER2 targeted positron emission tomography (PET) probes might be benefit for management of the disease. Small high-affinity scaffold proteins, affibodies, are ideal vectors for imaging HER2 overexpressed tumors. Despite of the initial success on development of F labeled ZHER affibody, the tedious synthesis producers, low yields and unfavorable pharmacokinetics may hinder the clinical use. Ga is an attractive positron emitter for PET imaging. A simple preparation of Ga labeled ZHER analog, Ga-NOTA-MAL-Cys-MZHER, was reported in the study. The performances of the tracer for assessing HER2 status in breast cancers were also evaluated.

METHODS

NOTA-MAL conjugated Cys-MZHER was radiolabeled with Ga. The probe was evaluated by tests including stability and cell binding studies in breast cancer cells with different HER2 levels. evaluation was performed in mice bearing tumors using microPET imaging and biodistribution experiments. A PET/CT imaging study was initially performed in patients with breast cancers.

RESULTS

The tracer was synthesized in a straightforward chelation method with satisfactory non-decay corrected yield (81±5%) and radiochemical purity (>95%). micro-PET imaging showed that HER2 high levels expressed BT474 xenografts were more clear visualized than HER2 low levels expressed MCF-7 tumors (16.12 ± 2.69 ID%/g 1.32 ± 0.19 ID%/g at 1 h post-injection). The outcome was consistent with the immunohistochemical analysis. No significant radioactivity was accumulated in healthy tissues (less than 2% ID/g) except kidneys. In a preliminary clinical study, Ga-NOTA-MAL-Cys-MZHER PET imaging allowed more high-contrast detection of HER2 positive primary tumors (maximum standardized uptake value = 2.16±0.27) than those in HER2 negative primary focus (maximum standardized uptake value = 0.32±0.05). No detectable side-effects were found.

CONCLUSION

In summary, this study indicates the significant efficiency of the Ga labeled HER2 affibody. Preclinical and clinical studies support the possibility of monitoring HER2 levels in breast cancers using Ga-NOTA-MAL-Cys-MZHER.

ADVANCES IN KNOWLEDGE

The research investigated the feasibility of a Ga labeled HER2 affibody modified with a hydrophilic linker for breast cancer PET imaging. Favorable outcomes showed that the probe might be valuable for determining HER2 status of the disease.